Skip to main content

Table 1  Demographic and clinical characteristics of study participants at ART initiation

From: Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African Cohort Study

 

All participants n = 443

 < 50 years n = 399

 ≥ 50 yearsn = 44

p value

Study site

0.18

 Kayunga, Uganda

94 (21.2%)

87 (21.8%)

7 (15.9%)

 

 South Rift Valley, Kenya

105 (23.7%)

90 (22.6%)

15 (34.1%)

 

 Kisumu West, Kenya

51 (11.5%)

47 (11.8%)

4 (9.1%)

 

 Mbeya, Tanzania

123 (27.8%)

108 (27.1%)

15 (34.1%)

 

 Abuja & Lagos Nigeria

70 (15.8%)

67 (16.8%)

3 (6.8%)

 

 Age at ART initiation (years), median (IQR)

36.4 (30.5, 43.2)

35.3 (29.9, 40.9)

55.25 (52.4, 59.1)

 < 0.001

Gender

0.07

 Male

184 (41.5%)

160 (40.1%)

24 (54.5%)

 

 Female

259 (58.5%)

239 (59.9%)

20 (45.5%)

 

Education

 < 0.01

 None or some primary

118 (26.6%)

97 (24.3%)

21 (47.7%)

 

 Primary or some secondary

197 (44.5%)

186 (46.6%)

11 (25.0%)

 

 Secondary and above

128 (28.9%)

116 (29.1%)

12 (27.3%)

 

Elevated blood pressure

 < 0.001

 No

401 (90.5%)

371 (93.0%)

30 (68.2%)

 

 Yes

42 (9.5%)

28 (7.0%)

14 (31.8%)

 

Dysglycemia

0.63

 No

367 (93.9%)

332 (94.1%)

35 (92.1%)

 

 Yes

24 (6.1%)

21 (5.9%)

3 (17.9%)

 

Hypercholesterolemia

0.10

 No

358 (89.7%)

326 (90.6%)

32 (82.1%)

 

 Yes

41 (10.3%)

31 (9.4%)

7 (17.9%)

 

CD4 nadir, median (IQR)

259 (122.5, 389)

257 (119.5, 384.5)

326.5 (141, 545.5)

0.22

ART regimen at initiation

0.62

 TDF/EFV/3TC

427 (96.4%)

384 (96.2%)

43 (97.7%)

 

 Other

16 (3.6%)

15 (3.8%)

1 (2.3%)

 
  1. IQR Interquartile Range, TDF tenofovir, EFV efavirenz, 3TC lamivudine, ART antiretroviral therapy